The Journal of dermatological treatment最新文献_第9页

Electrochemotherapy, as a novel therapeutic approach in the management of lentigo maligna, lentigo maligna melanoma, and acral lentiginous melanoma. 电疗，作为一种新的治疗方法，在管理恶性黄斑、恶性黄斑黑色素瘤和肢端黄斑黑色素瘤。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-04-29 DOI: 10.1080/09546634.2025.2495096

Petra Rózsa, Ildikó Csányi, Gábor Vass, Erika Varga, István Balázs Németh, Irma Korom, Henriette Ócsai, Eszter Baltás, Judit Oláh, Rolland Gyulai, Erika Kis

{"title":"Electrochemotherapy, as a novel therapeutic approach in the management of lentigo maligna, lentigo maligna melanoma, and acral lentiginous melanoma.","authors":"Petra Rózsa, Ildikó Csányi, Gábor Vass, Erika Varga, István Balázs Németh, Irma Korom, Henriette Ócsai, Eszter Baltás, Judit Oláh, Rolland Gyulai, Erika Kis","doi":"10.1080/09546634.2025.2495096","DOIUrl":"https://doi.org/10.1080/09546634.2025.2495096","url":null,"abstract":"Purpose: Lentigo maligna (LM), lentigo maligna melanoma (LMM), and acral lentiginous melanoma (ALM) are characterized by irregular borders and manifest on highly visible and/or surgically challenging areas. The challenge in treating these melanomas lies in preserving function and achieving satisfactory esthetic outcomes while ensuring complete surgical excision with an appropriate safety margin. We report three cases of elderly patients with LM, LMM, and ALM treated with electrochemotherapy (ECT).Materials and methods: All patients were treated according to the European Standard Operating Procedures of Electrochemotherapy protocol. Bleomycin was administered intravenously, followed by electroporation to allow better drug uptake into the tumor cells. The safety margin was ensured by electrode repositioning, and follow-up was scheduled regularly.Results: Our patients experienced favorable outcomes: two achieved a complete response, with one requiring adjuvant topical imiquimod for suspected residual disease, while the third patient achieved a partial response. No serious adverse events were observed, and cosmetic results were superior compared to extensive surgery.Conclusion: ECT appears to be a safe and effective treatment alternative for LM, LMM, and ALM, especially in elderly patients where surgery may lead to significant morbidity. ECT can be used alone or in combination with other therapies, providing a wide safety margin and cosmetically favorable results.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2495096"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative observation of the efficacy of Q-switched Nd:YAG laser with PhotoAcoustic Technology Pulse vs. traditional mode in treating melasma. 光声技术调q Nd:YAG激光脉冲与传统模式治疗黄褐斑的疗效对比观察。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-12 DOI: 10.1080/09546634.2025.2477257

Chen Ke, Yuzhen Huang, Changhan Chen, Xiaxia Chen, Youhui Ke

{"title":"Comparative observation of the efficacy of Q-switched Nd:YAG laser with PhotoAcoustic Technology Pulse vs. traditional mode in treating melasma.","authors":"Chen Ke, Yuzhen Huang, Changhan Chen, Xiaxia Chen, Youhui Ke","doi":"10.1080/09546634.2025.2477257","DOIUrl":"10.1080/09546634.2025.2477257","url":null,"abstract":"Background: Melasma is a common pigmentary skin disorder. Q-switched Nd:YAG laser therapy is commonly used, but its efficacy is limited. PhotoAcoustic Technology Pulse (PTP) mode is a newer technology that may enhance treatment outcomes.Objectives: To explore the comparative efficacy and safety of the Q-switched Nd:YAG laser with PTP mode versus the traditional single-pulse mode in the treatment of melasma.Methods: A retrospective study was conducted on 129 patients with chloasma in Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine from November 2016 to December 2018. The control group received the treatment with traditional mode. The study group was treated using PTP mode. The efficacy was evaluated using the Melasma Area and Severity Index (MASI) scores and patient satisfaction assessments.Results: The effective rate was 47.69% in the control group and 59.38% in the study group. There was a statistically significant improvement in MASI scores in both groups compared to baseline (p < 0.05), with the difference between the two groups also being statistically significant (p < 0.05).Conclusion: The Q-switched Nd:YAG laser treatment in PTP mode demonstrated superior efficacy in treating melasma compared to the traditional single-pulse mode, as evidenced by statistically significant improvements in MASI scores and higher patient satisfaction rates.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2477257"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics. Bimekizumab用于治疗中度至重度牛皮癣：来自两个意大利皮肤科诊所的52周真实世界经验。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-10 DOI: 10.1080/09546634.2024.2432932

E Mortato, F Artosi, C Borselli, I Compagnucci, Antonia Rivieccio, C Lanna, S Lambiase, R Gaeta Shumak, F Loconsole, L Bianchi, E Campione

{"title":"Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics.","authors":"E Mortato, F Artosi, C Borselli, I Compagnucci, Antonia Rivieccio, C Lanna, S Lambiase, R Gaeta Shumak, F Loconsole, L Bianchi, E Campione","doi":"10.1080/09546634.2024.2432932","DOIUrl":"10.1080/09546634.2024.2432932","url":null,"abstract":"Purpose: Psoriasis is a chronic, immune-mediated inflammatory skin condition marked by erythematous, scaly plaques. This retrospective observational study evaluated the long-term efficacy and safety of bimekizumab, a dual IL-17A and IL-17F inhibitor, in treating moderate to severe plaque psoriasis in 56 patients across two dermatology clinics in Italy.Materials and methods: Adult participants with a baseline Psoriasis Area and Severity Index (PASI) >10, or <10 with sensitive area involvement, were followed for 16 to 52 weeks. Clinical outcomes were measured by PASI 75, 90, and 100 responses and Dermatology Life Quality Index (DLQI) scores at 4, 16, 36, and 52 weeks.Results: At week 16, 97.5% of patients achieved PASI 75, 76.7% reached PASI 90, and 66% attained PASI 100. By week 52, 91.5% achieved PASI 90 and 85.1% reached PASI 100, with 95.7% reporting a Dermatology Life Quality Index (DLQI) score of 0 or 1, indicating minimal impact on daily life. The study found similar efficacy across bio-naïve and bio-experienced groups, and between normal-weight and obese patients, without statistically significant differences. The safety profile was consistent with previous trials, with oral candidiasis as the most frequent adverse event (21%).Conclusions: These findings support the efficacy and tolerability of bimekizumab for long-term psoriasis management.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2432932"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study. dupilumab治疗6岁以下特应性皮炎儿童的实际疗效和安全性：一项回顾性多中心研究

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-03 DOI: 10.1080/09546634.2025.2460578

Filip Rob, Blanka Pinkova, Kristyna Sokolova, Jana Kopuleta, Zuzana Jiraskova Zakostelska, Jana Cadova

{"title":"Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study.","authors":"Filip Rob, Blanka Pinkova, Kristyna Sokolova, Jana Kopuleta, Zuzana Jiraskova Zakostelska, Jana Cadova","doi":"10.1080/09546634.2025.2460578","DOIUrl":"10.1080/09546634.2025.2460578","url":null,"abstract":"In this multicentric real-world observational retrospective study, we evaluated the efficacy and safety of dupilumab for atopic dermatitis in children <6 years of age who underwent a minimum of 16 weeks of therapy. The analysis focused on EASI (Eczema Area and Severity Index), CDLQI (Children's Dermatology Life Quality Index), and Itch NRS (Numeric Rating Scale) changes from baseline to 4, 16, 24, 48, 72, and 96 weeks of follow-up (when available). Overall 24 children were included, with a mean age of 4.4 years. The baseline mean EASI among these patients was 26.7 (range 11.2-42.5). Since week 16 of therapy, all patients achieved and sustained at least 50% (EASI-50) atopic dermatitis improvement from baseline for the remainder of the follow-up period. At week 16, the mean EASI was 4.6 (0.8-13.1), EASI-75 reached 75% and EASI-90 38% of the patients. Within the initial 16 weeks of dupilumab treatment, 50% of patients experienced at least one adverse event, none of which were deemed severe. Conjunctivitis was among the most common adverse events (8.3%). In conclusion, dupilumab exhibited favorable tolerability, efficacy, and safety in children diagnosed with atopic dermatitis who were below the age of 6.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2460578"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating mTOR signaling pathway and sirolimus response in Benign lymphangioendothelioma. 良性淋巴管内皮瘤中mTOR信号通路及西罗莫司反应的研究。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-16 DOI: 10.1080/09546634.2025.2511114

Xin Wen, Daopei Zou, Fazhan Ban, Lei Wang

{"title":"Investigating mTOR signaling pathway and sirolimus response in Benign lymphangioendothelioma.","authors":"Xin Wen, Daopei Zou, Fazhan Ban, Lei Wang","doi":"10.1080/09546634.2025.2511114","DOIUrl":"https://doi.org/10.1080/09546634.2025.2511114","url":null,"abstract":"Background: Benign lymphangioendothelioma is a rare tumor originating from lymphatic vessels. Its underlying mechanisms remain unclear, and effective therapeutic interventions are limited.Objective: The goal of this study was to investigate the potential hyperactivation of the mTOR signaling pathway in benign lymphangioendothelioma. Additionally, to preliminarily assess the clinical efficacy and safety of the mTOR inhibitor sirolimus in management.Methods: Immunohistochemical staining was utilized to evaluate the activation status of mTOR pathway-related proteins in benign lymphangioendothelioma. Three patients with confirmed hyperactivation of the mTOR signaling pathway were administered with oral sirolimus, the clinical efficacy and safety of sirolimus tablets in treating benign lymphangioendothelioma were subsequently monitored.Results: A total of eight patients were included in this study. Immunohistochemical analysis was conducted on seven patients, overexpression of mTOR-related molecules was observed in each case. Three patients received treatment with oral sirolimus, and all three demonstrated significant regression of their skin lesions, with no notable adverse effects.Conclusion: The activation of mTOR signaling pathway is implicated in the pathogenesis of benign lymphangioendothelioma, suggesting a potential similarity in the underlying mechanisms with lymphatic malformations. The mTOR inhibitor sirolimus demonstrated promising therapeutic efficacy, accompanied by a favorable safety profile.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2511114"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review. Janus激酶抑制剂和生物制剂治疗类活体血管病变：系统综述。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-19 DOI: 10.1080/09546634.2025.2451804

Yu Liu, Tingting Li, Wei Shi

{"title":"Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review.","authors":"Yu Liu, Tingting Li, Wei Shi","doi":"10.1080/09546634.2025.2451804","DOIUrl":"10.1080/09546634.2025.2451804","url":null,"abstract":"Purpose: Livedoid vasculopathy (LV) is a chronic microvascular thrombosis disorder with an unclear pathogenesis, potentially involving hypercoagulability and inflammation. This systematic review aims to evaluate the efficacy and safety of Janus kinase (JAK) inhibitors and biologics in the treatment of LV.Materials and methods: A comprehensive search was conducted in PubMed, EMBASE, and the Cochrane Library on June 10, 2024, to identify relevant studies evaluating the use of JAK inhibitors and biologics in LV treatment.Results: A total of 15 articles were included in the review. Among the 41 patients treated with biologics and JAK inhibitors, 36 (87.8%) showed positive clinical responses, including significant improvements in pain relief. TNF-α inhibitors were the most commonly used monotherapy, followed by JAK inhibitors. Adverse events were infrequent, suggesting that these treatments generally have a favorable safety profile.Conclusions: JAK inhibitors and biologics appear to be safe and effective alternatives for managing refractory LV. These findings provide a foundation for future studies to further validate their clinical effectiveness and long-term safety.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2451804"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis. 牛皮癣患者切换生物制剂：系统回顾和荟萃分析。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-22 DOI: 10.1080/09546634.2025.2521082

LiHong Zhang, XiTong Zhao, WenChao Li, YuanQiang Sun, Hong Liu

{"title":"Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis.","authors":"LiHong Zhang, XiTong Zhao, WenChao Li, YuanQiang Sun, Hong Liu","doi":"10.1080/09546634.2025.2521082","DOIUrl":"10.1080/09546634.2025.2521082","url":null,"abstract":"Background: Multiple biologics are available for psoriasis treatment, but switching treatments is often necessary at some point. The choice between intraclass or interclass biologic switching has not been extensively investigated.Methods: Two independent authors searched the databases PubMed and EMBASE for studies reporting on biologic switching in psoriasis patients. Our study was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines.Results: A total of 19 publications, comprising 679 patients, were included. The intraclass switching group consisted of 519 patients, while the interclass switching group included 139 patients. For intraclass switching, there are respectively 160, 326 and 33 patients switched of TNF-α, IL-17, IL-23. For interclass switching, 11 patients switched from TNF-α to IL-17, 6 from IL-17 to IL-23, 41 from IL-17 to IL-12/23, 29 from IL-17 to TNF-α, 15 from IL-12/23 to IL-17, 8 from IL-12/23 to IL-23. After 12 weeks, the proportion of patients achieving Psoriasis Area and Severity Index (PASI)75 was significantly higher in the intraclass switching group compared to the interclass switching group. However, after 16-52 weeks, the PASI75 proportions were comparable between the groups.Conclusion: Intraclass switching shows better short-term efficacy than interclass switching. However, in the long term, both switching strategies are effective and safe. This study also shows that adalimumab, ixekizumab, and risankizumab are the preferred agents for intraclass switching, whereas guselkumab serves as the primary agent for interclass transitions.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2521082"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical delgocitinib for the treatment of chronic hand eczema. 局部delgocitinib治疗慢性手部湿疹。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-17 DOI: 10.1080/09546634.2025.2479126

Asaad Abdelhalim, Orhan Yilmaz, Mohamed Elshaikh Berair, Tiago Torres

{"title":"Topical delgocitinib for the treatment of chronic hand eczema.","authors":"Asaad Abdelhalim, Orhan Yilmaz, Mohamed Elshaikh Berair, Tiago Torres","doi":"10.1080/09546634.2025.2479126","DOIUrl":"10.1080/09546634.2025.2479126","url":null,"abstract":"Purpose: Chronic hand eczema (CHE) is a prevalent dermatological condition characterized by significant morbidity and impaired quality of life. Delgocitinib, a pan-JAK inhibitor, has emerged as a promising topical treatment for CHE, targeting key cytokine-mediated inflammatory pathways involved in the disease. Delgocitinib 20 mg/g (2%) cream was approved by the European Medicines Agency (EMA) in 2024 for moderate-to-severe CHE, and its U.S. Food and Drug Administration (FDA) review is currently in progress.Materials and methods: PubMed, Medline and ClinicalTrials.gov were searched up to January 21, 2025, using specific search terms related to delgocitinib and chronic hand eczema.Results and conclusions: Clinical trials have demonstrated its effectiveness in improving disease severity, including eczema signs and symptoms such as pain and itching, and enhancing patient-reported outcomes compared to vehicle. Topical delgocitinib has shown a favorable safety profile, with most adverse events being mild and unrelated to treatment. Serious adverse events were rare, and treatment discontinuation due to adverse events was minimal. This narrative review synthesizes current evidence on topical delgocitinib's clinical utility and safety in CHE, positioning it as a valuable therapeutic option. Further comparative studies are needed to evaluate its efficacy against oral JAK inhibitors and other topical immunosuppressants, providing insight into optimizing treatment strategies for this chronic condition.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2479126"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalized prediction of psoriasis relapse post-biologic discontinuation: a machine learning-driven population cohort study. 生物停药后银屑病复发的个性化预测：一项机器学习驱动的人群队列研究。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-19 DOI: 10.1080/09546634.2025.2480743

Shan Huang, Yanping Bai, Ruozhou Qi, Hongda Yu, Xingwu Duan

{"title":"Personalized prediction of psoriasis relapse post-biologic discontinuation: a machine learning-driven population cohort study.","authors":"Shan Huang, Yanping Bai, Ruozhou Qi, Hongda Yu, Xingwu Duan","doi":"10.1080/09546634.2025.2480743","DOIUrl":"10.1080/09546634.2025.2480743","url":null,"abstract":"Background: Identifying the risk of psoriasis relapse after discontinuing biologics can help optimize treatment strategies, potentially reducing relapse rates and alleviating the burden of disease management.Objective: To develop and validate a personalized prediction model for psoriasis relapse following the discontinuation of biologics.Methods: This study enrolled patients who achieved remission following biologic therapy. Relapse predictors were identified using the Boruta algorithm combined with multivariate Cox regression. A nomogram and an online calculator were created to aid in the visualization and computation of outcomes. The model's performance was thoroughly assessed using Receiver Operating Characteristic (ROC) curves, Area Under the Curve (AUC), C-statistics, calibration plots, and Decision Curve Analysis (DCA).Results: The study included 597 patients, with 534 in the derivation cohort and 63 in the validation cohort. Anxiety, disease duration, prior biologic treatments, treatment duration, time to achieve PASI 75, and maximum PASI response were identified as influential factors for relapse and were incorporated into the model. Both internal and external evaluations indicate that the model exhibits good predictive accuracy.Conclusion: A multivariate model leveraging standard clinical data can relatively accurately predict the risk of psoriasis relapse post-biologic discontinuation, guiding personalized treatment strategies.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2480743"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline. 用spesolimab，中剂量皮质类固醇和米诺环素成功治疗依那西普和阿达木单抗耐药坏疽性脓皮病。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-01-19 DOI: 10.1080/09546634.2025.2451811

Hanlin Zhang, Chao Wu, Hongzhong Jin

{"title":"Successful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline.","authors":"Hanlin Zhang, Chao Wu, Hongzhong Jin","doi":"10.1080/09546634.2025.2451811","DOIUrl":"10.1080/09546634.2025.2451811","url":null,"abstract":"Purpose: Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis characterized by rapidly developing, painful ulcers. This study explores the potential of spesolimab, an anti-IL-36R antibody, as a therapeutic option for refractory PG.Materials and methods: We report a case of a 48-year-old male with refractory PG who failed to respond to etanercept and adalimumab. Upon admission, the patient presented with extensive, painful ulcerations on the trunk and extremities. He was started on oral methylprednisolone (32 mg/day) and minocycline (50 mg twice daily). After a week, minimal improvement was observed. After reviewing the screening results and discussing treatment options, the patient received two doses of spesolimab (900 mg intravenously) administered two weeks apart.Results: Marked clinical improvement was observed after spesolimab initiation. Complete ulcer healing was achieved within six weeks of starting spesolimab, with no adverse effects reported.Conclusions: This case demonstrates the potential efficacy of spesolimab for treating refractory PG, particularly in patients unresponsive to TNF-α inhibitors. Despite the added complexity of the patient's underlying HBV infection and elevated M-protein, no HBV reactivation or other hematologic complications occurred. Further studies are needed to validate its role in managing PG and other neutrophilic dermatoses.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2451811"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0